Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-39859
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
s12916-020-01643-5.pdf | 710,53 kB | Adobe PDF | Öffnen/Anzeigen |
Titel: | Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study |
VerfasserIn: | Emrich, Insa E. Lizzi, Fabio Siegel, Jonathan David ![]() Seiler-Mussler, Sarah Ukena, Christian Kaddu-Mulindwa, Dominic D'Amelio, Roberto Wagenpfeil, Stefan ![]() Brandenburg, Vincent M. Böhm, Michael Fliser, Danilo Heine, Gunnar H. |
Sprache: | Englisch |
In: | |
Titel: | BMC medicine |
Bandnummer: | 18 |
Heft: | 1 |
Verlag/Plattform: | BioMed Central |
Erscheinungsjahr: | 2020 |
Freie Schlagwörter: | Hypophosphatemia FGF23 Iron deficiency anemia Ferric carboxymaltose Ferric derisomaltose |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Background In patients with iron deficiency anemia, ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) allow high-dose iron repletion. While FCM is reported to induce hypophosphatemia, the frequency of hypophosphatemia after an equivalent dosage of FDI had not been assessed prospectively. Methods In the prospective, single-center, double-blind HOMe aFers study, 26 women with iron deficiency anemia (hemoglobin < 12 g/dL plus either plasma ferritin ≤ 100 ng/mL or a plasma ferritin ≤ 300 ng/mL and transferrin saturation (TSAT) ≤ 30%) were randomized to a single intravenous infusion of 20 mg/kg body weight (up to a maximum of 1000 mg) FCM or FDI. The primary endpoint was the incidence of hypophosphatemia (plasma phosphorus levels < 2.0 mg/dL at day 1, day 7 ± 2, and/or day 35 ± 2 after the infusion). In order to investigate potential skeletal and cardiovascular implications, we assessed changes in other components of mineral and bone metabolism, left ventricular function, and arrhythmias. Results Hypophosphatemia occurred more frequently in women treated with FCM (9 out of 12 [75%]) than in those treated with FDI (1 out of 13 [8%]; p = 0.001). Within 24 h after iron supplementation, women in the FCM group had significant higher plasma intact FGF23 (p < 0.001) and lower plasma 1.25-dihydroxyvitamin D (p < 0.001). As an indicator of urinary phosphorus losses, urinary fractional phosphorus excretion was higher in the FCM group (p = 0.021 at day 7 ± 2 after iron supplementation). We did not observe differences in skeletal and cardiovascular markers, potentially because of the limited number of participants. Conclusions While both FCM and FDI provide efficient iron repletion in participants with iron deficiency anemia, FCM induced hypophosphatemia more often than FDI. Trial registration Clinical Trials.gov NCT02905539. Registered on 8 September 2016. 2015-004808-36 (EudraCT Number) U1111-1176-4563 (WHO Universal Trial Number) DRKS00010766 (Deutsches Register Klinischer Studien) |
DOI der Erstveröffentlichung: | 10.1186/s12916-020-01643-5 |
URL der Erstveröffentlichung: | https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01643-5 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-398594 hdl:20.500.11880/35896 http://dx.doi.org/10.22028/D291-39859 |
ISSN: | 1741-7015 |
Datum des Eintrags: | 26-Mai-2023 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Innere Medizin |
Professur: | M - Prof. Dr. Michael Böhm M - Prof. Dr. Danilo Fliser M - Prof. Dr. Stefan Wagenpfeil |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons